Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS.

Seibold M, Stühmer T, Kremer N, Mottok A, Scholz CJ, Schlosser A, Leich E, Holzgrabe U, Brünnert D, Barrio S, Kortüm KM, Solimando AG, Chatterjee M, Einsele H, Rosenwald A, Bargou RC, Steinbrunn T.

Haematologica. 2019 Oct 10. pii: haematol.2019.223024. doi: 10.3324/haematol.2019.223024. [Epub ahead of print]

2.

Reproducing the Molecular Subclassification of Peripheral T-cell Lymphoma-NOS by Immunohistochemistry.

Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone WG, Bouska A, D'amore F, Bjerregård Pedersen M, Pileri SA, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J.

Blood. 2019 Sep 27. pii: blood.2019000779. doi: 10.1182/blood.2019000779. [Epub ahead of print]

PMID:
31562134
3.

Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling.

Zhang AW, O'Flanagan C, Chavez EA, Lim JLP, Ceglia N, McPherson A, Wiens M, Walters P, Chan T, Hewitson B, Lai D, Mottok A, Sarkozy C, Chong L, Aoki T, Wang X, Weng AP, McAlpine JN, Aparicio S, Steidl C, Campbell KR, Shah SP.

Nat Methods. 2019 Oct;16(10):1007-1015. doi: 10.1038/s41592-019-0529-1. Epub 2019 Sep 9.

PMID:
31501550
4.

The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.

Hartmann S, Plütschow A, Mottok A, Bernd HW, Feller AC, Ott G, Cogliatti S, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Rosenwald A, Engert A, Hansmann ML, Eichenauer DA.

Am J Hematol. 2019 Nov;94(11):1208-1213. doi: 10.1002/ajh.25607. Epub 2019 Aug 21.

PMID:
31396979
5.

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.

Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E, Sarkozy C, Gascoyne RD, Connors JM, Ben-Neriah S, Mungall A, Marra MA, Siebert R, Scott DW, Savage KJ, Steidl C.

Blood. 2019 Sep 5;134(10):802-813. doi: 10.1182/blood.2019001126. Epub 2019 Jul 10.

PMID:
31292115
6.

Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.

Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, Sehn LH, Connors JM, Gascoyne RD, Feldman AL, Farinha P, Steidl C, Scott DW, Slack GW, Savage KJ.

Br J Haematol. 2019 Aug;186(3):e28-e31. doi: 10.1111/bjh.15860. Epub 2019 Mar 14. No abstract available.

PMID:
30873584
7.

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C.

Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.

PMID:
30705065
8.

Convergence of risk prediction models in follicular lymphoma.

Silva A, Bassim S, Sarkozy C, Mottok A, Lackraj T, Jurinovic V, Brodtkorb M, Lingjaerde OC, Sehn LH, Gascoyne RD, Weigert O, Steidl C, Kridel R.

Haematologica. 2019 Jun;104(6):e252-e255. doi: 10.3324/haematol.2018.209031. Epub 2019 Jan 3. No abstract available.

9.

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.

J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.

PMID:
30523716
10.

Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.

Sarkozy C, Copie-Bergman C, Damotte D, Ben-Neriah S, Burroni B, Cornillon J, Lemal R, Golfier C, Fabiani B, Chassagne-Clément C, Parrens M, Herbaux C, Xerri L, Bossard C, Laurent C, Cheminant M, Cartron G, Cabecadas J, Molina T, Salles G, Steidl C, Ghesquières H, Mottok A, Traverse-Glehen A.

Am J Surg Pathol. 2019 Mar;43(3):341-351. doi: 10.1097/PAS.0000000000001198.

PMID:
30540571
11.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

12.

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD.

Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.

13.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

PMID:
30257882
14.

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.

Br J Haematol. 2019 Feb;184(4):616-624. doi: 10.1111/bjh.15519. Epub 2018 Aug 10.

PMID:
30095158
15.

Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies.

Mottok A, Steidl C.

Blood. 2018 Apr 12;131(15):1654-1665. doi: 10.1182/blood-2017-09-772632. Epub 2018 Mar 2. Review.

PMID:
29500175
16.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A.

Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.

17.

Methotrexate-induced lymphoproliferative disorders: regression matters.

Mottok A, Rosenwald A.

Leuk Lymphoma. 2018 May;59(5):1027-1029. doi: 10.1080/10428194.2018.1437270. Epub 2018 Feb 22. No abstract available.

PMID:
29468914
18.

Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation.

Viganò E, Gunawardana J, Mottok A, Van Tol T, Mak K, Chan FC, Chong L, Chavez E, Woolcock B, Takata K, Twa D, Shulha HP, Telenius A, Kutovaya O, Hung SS, Healy S, Ben-Neriah S, Leroy K, Gaulard P, Diepstra A, Kridel R, Savage KJ, Rimsza L, Gascoyne R, Steidl C.

Blood. 2018 May 3;131(18):2036-2046. doi: 10.1182/blood-2017-09-808907. Epub 2018 Feb 21.

PMID:
29467182
19.

Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer.

Samnick S, Al-Momani E, Schmid JS, Mottok A, Buck AK, Lapa C.

Clin Nucl Med. 2018 Mar;43(3):162-167. doi: 10.1097/RLU.0000000000001977.

PMID:
29356744
20.

The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.

Twa DDW, Mottok A, Savage KJ, Steidl C.

Blood Rev. 2018 May;32(3):249-255. doi: 10.1016/j.blre.2017.12.001. Epub 2017 Dec 20. Review.

PMID:
29289361
21.

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R.

Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9.

22.

Observation as the initial management strategy in patients with mantle cell lymphoma.

Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, Connors JM, Sehn LH, Savage KJ, Gerrie AS, Villa D.

Ann Oncol. 2017 Oct 1;28(10):2489-2495. doi: 10.1093/annonc/mdx333.

PMID:
28961827
23.

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.

Chan FC, Mottok A, Gerrie AS, Power M, Nijland M, Diepstra A, van den Berg A, Kamper P, d'Amore F, d'Amore AL, Hamilton-Dutoit S, Savage KJ, Shah SP, Connors JM, Gascoyne RD, Scott DW, Steidl C.

J Clin Oncol. 2017 Nov 10;35(32):3722-3733. doi: 10.1200/JCO.2017.72.7925. Epub 2017 Sep 12.

PMID:
28898161
24.

Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma.

Li PC, Siddiqi IN, Mottok A, Loo EY, Wu CH, Cozen W, Steidl C, Shih JC.

J Pathol. 2017 Oct;243(2):220-229. doi: 10.1002/path.4944. Epub 2017 Sep 5.

25.

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW.

Blood. 2017 May 18;129(20):2760-2770. doi: 10.1182/blood-2016-11-747022. Epub 2017 Mar 28.

PMID:
28351934
26.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

27.

IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma.

Pandey S, Mourcin F, Marchand T, Nayar S, Guirriec M, Pangault C, Monvoisin C, Amé-Thomas P, Guilloton F, Dulong J, Coles M, Fest T, Mottok A, Barone F, Tarte K.

Blood. 2017 May 4;129(18):2507-2518. doi: 10.1182/blood-2016-08-737239. Epub 2017 Feb 15.

28.

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.

Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP.

PLoS Med. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec.

29.

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.

Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, Tam W, Teruya-Feldstein J, de Stanchina E, Chan WC, Malek SN, Ennishi D, Brentjens RJ, Gascoyne RD, Cogné M, Tarte K, Wendel HG.

Cell. 2016 Oct 6;167(2):405-418.e13. doi: 10.1016/j.cell.2016.08.032. Epub 2016 Sep 29.

30.

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.

Müller E, Bauer S, Stühmer T, Mottok A, Scholz CJ, Steinbrunn T, Brünnert D, Brandl A, Schraud H, Kreßmann S, Beilhack A, Rosenwald A, Bargou RC, Chatterjee M.

Leukemia. 2017 Apr;31(4):922-933. doi: 10.1038/leu.2016.264. Epub 2016 Sep 30.

PMID:
27686868
31.

Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.

Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, Vaeth M, Kuen J, Holtappels R, Podlech J, Mottok A, Kraus S, Jordán-Garrote AL, Bäuerlein CA, Brede C, Ribechini E, Fick A, Seher A, Polz J, Ottmüller KJ, Baker J, Nishikii H, Ritz M, Mattenheimer K, Schwinn S, Winter T, Schäfer V, Krappmann S, Einsele H, Müller TD, Reddehase MJ, Lutz MB, Männel DN, Berberich-Siebelt F, Wajant H, Beilhack A.

J Exp Med. 2016 Aug 22;213(9):1881-900. doi: 10.1084/jem.20151563. Epub 2016 Aug 15.

32.

Nodular lymphocyte-predominant Hodgkin lymphoma.

Savage KJ, Mottok A, Fanale M.

Semin Hematol. 2016 Jul;53(3):190-202. doi: 10.1053/j.seminhematol.2016.05.009. Epub 2016 May 13. Review.

PMID:
27496311
33.

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.

Chong LC, Twa DD, Mottok A, Ben-Neriah S, Woolcock BW, Zhao Y, Savage KJ, Marra MA, Scott DW, Gascoyne RD, Morin RD, Mungall AJ, Steidl C.

Blood. 2016 Sep 1;128(9):1206-13. doi: 10.1182/blood-2015-11-683003. Epub 2016 Jun 7.

PMID:
27268263
34.

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL.

Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, Steidl C, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD.

Blood. 2016 May 5;127(18):2182-8. doi: 10.1182/blood-2015-10-676700. Epub 2016 Feb 1.

PMID:
26834242
35.

Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, Hung S, Rosenwald A, Gascoyne R, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Xiao W, Borgstahl GE, Davis S, Steidl C, McKeithan T, Iqbal J, Chan WC.

Leukemia. 2016 May;30(5):1062-70. doi: 10.1038/leu.2015.357. Epub 2015 Dec 31.

36.

Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.

Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C.

Cell Rep. 2015 Nov 17;13(7):1418-1431. doi: 10.1016/j.celrep.2015.10.008. Epub 2015 Nov 5.

37.

Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.

Distler E, Albrecht J, Brunk A, Khan S, Schnürer E, Frey M, Mottok A, Jordán-Garrote AL, Brede C, Beilhack A, Mades A, Tomsitz D, Theobald M, Herr W, Hartwig UF.

Int J Cancer. 2016 Mar 1;138(5):1256-68. doi: 10.1002/ijc.29854. Epub 2015 Oct 5.

38.

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, Hother C, Liu S, Cao XJ, Tam W, Shaknovich R, Garcia BA, Gascoyne RD, Ge K, Shilatifard A, Elemento O, Nussenzweig A, Melnick AM, Wendel HG.

Nat Med. 2015 Oct;21(10):1199-208. doi: 10.1038/nm.3943. Epub 2015 Sep 14.

39.

Cell of origin of transformed follicular lymphoma.

Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD.

Blood. 2015 Oct 29;126(18):2118-27. doi: 10.1182/blood-2015-06-649905. Epub 2015 Aug 25.

40.

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O.

Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.

PMID:
26256760
41.

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD.

J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.

42.

Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility.

Kreft A, Mottok A, Mesteri I, Cardona DM, Janin A, Kühl AA, Andrulis M, Brunner A, Shulman HM, Negri G, Tzankov A, Huber E; Gastrointestinal Pathology Group of the German-Austrian-Swiss GvHD Consortium.

Virchows Arch. 2015 Sep;467(3):255-63. doi: 10.1007/s00428-015-1803-y. Epub 2015 Jul 12.

PMID:
26164839
43.

Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.

Yuan J, Wright G, Rosenwald A, Steidl C, Gascoyne RD, Connors JM, Mottok A, Weisenburger DD, Greiner TC, Fu K, Smith L, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Ott G, Vose JM, Staudt LM, Chan WC; Lymphoma Leukemia Molecular Profiling Project (LLMPP).

Am J Surg Pathol. 2015 Oct;39(10):1322-30. doi: 10.1097/PAS.0000000000000473.

PMID:
26135560
44.

Genomic alterations underlying immune privilege in malignant lymphomas.

Mottok A, Steidl C.

Curr Opin Hematol. 2015 Jul;22(4):343-54. doi: 10.1097/MOH.0000000000000155. Review.

PMID:
26049756
45.

Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.

Chopra M, Brandl A, Siegmund D, Mottok A, Schäfer V, Biehl M, Kraus S, Bäuerlein CA, Ritz M, Mattenheimer K, Schwinn S, Seher A, Grabinger T, Einsele H, Rosenwald A, Brunner T, Beilhack A, Wajant H.

Blood. 2015 Jul 23;126(4):437-44. doi: 10.1182/blood-2015-01-620583. Epub 2015 May 26.

46.

Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.

Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, Mottok A, Ennishi D, Johnson NA, Steidl C, Connors JM, Morin RD, Gascoyne RD, Marra MA.

Genome Biol. 2015 Jan 29;16:18. doi: 10.1186/s13059-014-0568-y.

47.

Recurrent genomic rearrangements in primary testicular lymphoma.

Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, Steidl C.

J Pathol. 2015 Jun;236(2):136-41. doi: 10.1002/path.4522. Epub 2015 Mar 26.

PMID:
25712539
48.

Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.

Vaeth M, Bäuerlein CA, Pusch T, Findeis J, Chopra M, Mottok A, Rosenwald A, Beilhack A, Berberich-Siebelt F.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1125-30. doi: 10.1073/pnas.1409290112. Epub 2015 Jan 12.

49.

Performance of cone beam computed tomography in comparison to conventional imaging techniques for the detection of bone invasion in oral cancer.

Linz C, Müller-Richter UD, Buck AK, Mottok A, Ritter C, Schneider P, Metzen D, Heuschmann P, Malzahn U, Kübler AC, Herrmann K, Bluemel C.

Int J Oral Maxillofac Surg. 2015 Jan;44(1):8-15. doi: 10.1016/j.ijom.2014.07.023. Epub 2014 Oct 28.

PMID:
25442744
50.

An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.

Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, Johnson N, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, Steidl C.

Blood. 2015 Feb 5;125(6):959-66. doi: 10.1182/blood-2013-06-507152. Epub 2014 Nov 13.

PMID:
25395426

Supplemental Content

Loading ...
Support Center